SEEL
Closed
Seelos Therapeutics Inc
0.28
-0.11 (-28.21%)
Last Update: 16 Dec 2024 17:30:00
Yesterday: 0.39
Day's Range: 0.25 - 0.35
Send
sign up or login to leave a comment!
When Written:
0.8199
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company that specializes in developing therapeutics for central nervous system (CNS) disorders. The company is focused on developing innovative treatments for neurological and psychiatric disorders, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Sanfilippo syndrome.
Seelos Therapeutics was founded in 2016 and is headquartered in New York City. The company's lead product candidate is SLS-002, a potential treatment for acute suicidal ideation and behavior in patients with major depressive disorder.
Seelos Therapeutics is also developing other CNS disorder treatments, including SLS-005 for Parkinson's disease and SLS-007 for ALS. The company's mission is to improve the lives of patients suffering from CNS disorders by developing innovative and effective treatments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Seelos Therapeutics was founded in 2016 and is headquartered in New York City. The company's lead product candidate is SLS-002, a potential treatment for acute suicidal ideation and behavior in patients with major depressive disorder.
Seelos Therapeutics is also developing other CNS disorder treatments, including SLS-005 for Parkinson's disease and SLS-007 for ALS. The company's mission is to improve the lives of patients suffering from CNS disorders by developing innovative and effective treatments.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








